Search results for Iscalimab

Iscalimab Biosimilar – Anti-CD40, TNFRSF5 mAb – Research Grade, ProteoGenix, PX-TA1503

Description of Iscalimab Biosimilar - Anti-CD40, TNFRSF5 mAb - Research Grade Introduction Iscalimab Biosimilar, also known as Anti-CD40, TNFRSF5 mAb, is a research grade monoclonal antibody that targets the CD40 protein, a member of the tumor necrosis factor receptor superfamily. This antibody has shown promising potential as a therapeutic agent in various diseases, making it a subject of extensive research and development. Structure of Iscalimab Biosimilar Iscalimab Biosimilar is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a high affinity and specificity for its target. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of 21 days. Mechanism of Action CD40 is a cell surface protein found on various immune cells, including B cells, dendritic cells, and macrophages. It plays a crucial role in the activation and differentiation of these immune cells, making it an attractive therapeutic target for various diseases. Iscalimab Biosimilar binds to CD40 and blocks its interaction with its ligand, CD154. This prevents the activation of downstream signaling pathways, leading to inhibition of immune cell activation and proliferation. Applications in Disease Treatment Iscalimab Biosimilar has shown promising results in preclinical and clinical studies as a potential treatment for various diseases. Here are some of its potential applications: 1. Autoimmune Diseases: CD40 plays a crucial role in the development of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Iscalimab Biosimilar has shown promising results in preclinical studies as a potential treatment for these diseases by inhibiting the activation of autoreactive immune cells. 2. Transplant Rejection: CD40-CD154 interaction is known to play a critical role in acute and chronic rejection of transplanted organs. Iscalimab Biosimilar has shown potential in preventing transplant rejection by blocking this interaction and reducing the activation of immune cells. 3. Cancer: CD40 is also expressed on the surface of tumor cells and has been linked to tumor growth and survival. Iscalimab Biosimilar has shown promising results in preclinical studies as a potential treatment for various cancers, including lymphoma, leukemia, and solid tumors, by inhibiting the activation of immune cells and promoting tumor cell death. 4. Infectious Diseases: CD40 is involved in the immune response against various infectious agents, including viruses and bacteria. Iscalimab Biosimilar has shown potential in enhancing the immune response against these pathogens by blocking CD40 and promoting the activation of immune cells. Conclusion Iscalimab Biosimilar is a research grade monoclonal antibody that targets the CD40 protein and has shown promising results as a potential treatment for various diseases. Its unique mechanism of action and potential applications make it a subject of extensive research and development. Further studies and clinical trials are needed to fully understand the therapeutic potential of Iscalimab Biosimilar and its role in the treatment of various diseases.

Iscalimab, Abbexa, abx831463

Iscalimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40/TNFRSF5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Iscalimab (CFZ533) is a new, fully humanized monoclonal antibody that targets cluster of differentiation 40 (CD40), which can regulate the CD40-CD154 costimulatory pathway and prevent CD40 pathway signal transduction and CD40+ cell type activation. It is expected Become a new treatment for solid organs and related autoimmune diseases.

Iscalimab, Kyinno, KB-1592

Iscalimab ELISA Kit, ProteoGenix, KPTX212

Description of Iscalimab ELISA Kit Introduction The Iscalimab ELISA Kit is a powerful tool for the detection and quantification of Iscalimab in various biological samples. Iscalimab, also known as CFZ533, is a fully human monoclonal antibody that targets the CD40-CD154 co-stimulatory pathway. This pathway plays a crucial role in the activation of T cells, making Iscalimab a promising therapeutic target for various autoimmune diseases and transplant rejection. In this article, we will discuss the structure, activity, and applications of the Iscalimab ELISA Kit in detail. Structure of Iscalimab Iscalimab is a 150 kDa glycosylated monoclonal antibody, composed of two heavy chains and two light chains. The heavy chains consist of a constant region and a variable region, while the light chains only have a variable region. The variable regions of both the heavy and light chains determine the specificity of Iscalimab for its target, CD40. The constant region of the heavy chains plays a role in the effector functions of Iscalimab, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Mechanism of Action Iscalimab works by binding to CD40 on the surface of T cells, blocking the interaction between CD40 and its ligand, CD154. This prevents the activation of T cells and subsequent production of inflammatory cytokines, such as interleukin-2 and interferon-gamma. Iscalimab also promotes the generation of regulatory T cells, which suppress immune responses and promote tolerance. These mechanisms make Iscalimab a potent immunosuppressant and a promising therapeutic option for autoimmune diseases and transplant rejection. Applications of Iscalimab ELISA Kit The Iscalimab ELISA Kit is a valuable tool for measuring the levels of Iscalimab in various biological samples, such as serum, plasma, and cell culture supernatants. This assay utilizes a sandwich enzyme-linked immunosorbent assay (ELISA) format, where a capture antibody specific for Iscalimab is coated onto a microplate. The Iscalimab present in the sample is then bound by the capture antibody, followed by the addition of a detection antibody specific for a different epitope on Iscalimab. The detection antibody is conjugated to an enzyme, which produces a colorimetric signal upon addition of a substrate. The intensity of this signal is directly proportional to the amount of Iscalimab present in the sample, allowing for accurate quantification. The Iscalimab ELISA Kit has several applications in research and clinical settings. In research, it can be used to monitor the pharmacokinetics of Iscalimab in preclinical and clinical studies. It can also be used to measure the levels of Iscalimab in patient samples to assess its efficacy as a therapeutic agent. In clinical settings, the Iscalimab ELISA Kit can be used to guide dosing and monitor treatment response in patients receiving Iscalimab therapy. Conclusion The Iscalimab ELISA Kit is a valuable tool for the detection and quantification of Iscalimab, a promising therapeutic antibody targeting the CD40-CD154 co-stimulatory pathway. Its accurate and sensitive measurement of Iscalimab levels in various biological samples makes it a valuable asset in research and clinical settings. With the increasing interest in Iscalimab as a therapeutic agent, the Iscalimab ELISA Kit is expected to play a crucial role in the development and monitoring of Iscalimab-based therapies for autoimmune diseases and transplant rejection. Keywords Antibody, therapeutic target, Iscalimab, CFZ533, CD40-CD154 co-stimulatory pathway, T cells, autoimmune diseases, transplant rejection, ELISA, pharmacokinetics, treatment response.

Iscalimab ELISA Kit, Abbexa, abx395101

Iscalimab ELISA Kit is a quantitative ELISA kit for detection of Iscalimab.Iscalimab is a new, fully human, monoclonal antibody preventing cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types. In a recent multicenter, randomized control trial (NCT02217410), with the primary endpoint of non-inferiority on the composite endpoint, iscalimab therapy showed non-inferiority on a composite clinical endpoint, improved renal function, reduced risk for new onset diabetes and similar safety compared with tacrolimus. The analysis presented at the ATC included patients from this study that underwent either routine biopsies or biopsies as part of a follow-up protocol. The data was reviewed and scored by a blinded pathologist using the established Banff criteria and CADI. A CADI of 1 or less was considered as 'normal renal histology'. The average CADI at final biopsy was 1.6 ±0.6 for iscalimab and 5.1 ±0.8 for tacrolimus.

Iscalimab Biosimilar - Research Grade, ichor.bio, ICH5610

Research Grade Iscalimab (HB782016), abinScience, HB782016